News Related to Tremor

Related coverage linked through entity extraction aliases.

FDA approves Bristol Myers Squibb’s Breyanzi for relapsed or refractory marginal zone lymphoma

May 18, 2026

The FDA approved Bristol Myers Squibb’s Breyanzi for adults with relapsed or refractory marginal zone lymphoma after at least two prior systemic therapies. In TRANSCEND FL, the CAR T therapy showed a 95.5% overall response rate and 62.1% complete response rate.

FDA clears neuromodulation devices from Epineuron, Aneuvo and Encora

May 14, 2026

The FDA cleared neuromodulation devices from Epineuron, Aneuvo and Encora Therapeutics. The products address peripheral nerve surgery, spinal cord injury neurorehabilitation and essential tremor.